FDA clears Insulet OmniPod Dash as insulin pump alternative

Insulet has won FDA clearance to market its Omnipod Dash alternate controller-enabled (ACE) infusion pump as an integrated insulin pump.

The American company received FDA clearance for the Omnipod Dash in June 2018 and launched the device in early 2019. The latest indication states that the pump can reliably and securely communicate with compatible devices.

The Omnipod system is a continuous insulin delivery system designed with a tubeless, waterproof, Bluetooth-enabled pod capable of holding up to 200 units of U-100 insulin and a touch-screen personal diabetes manager to control the pod.

Insulet’s President and CEO Shacey Petrovic commented, “The diabetes industry is a dynamic and evolving landscape with technological and regulatory advancements enabling more interoperability and more patient choice in treatments and disease management. Omnipod Dash was designed with interoperability in mind, and we’re thrilled to provide people with diabetes the choice and flexibility to manage their diabetes on their own terms. We commend the FDA’s interoperability efforts and look forward to working with the agency as we continue to deliver our robust innovation pipeline.”

Last month, Insulet launched of the Omnipod Display and Omnipod View apps in the iOS app store to go along with the Omnipod device.

As reported by Sean Whooley for Drug Delivery Business.

Sign me up!
Open publication